MannKind's ReadyFlow Autoinjector: A Game Changer For Heart Failure Patients
MannKind Corporation delivered strong Q3 '25 results, beating EPS and revenue estimates, and shares have responded positively. The FDA accepted the supplemental New Drug Application for the FUROSCIX ReadyFlow Autoinjector, offering rapid furosemide delivery for CHF and CKD patients. I see a substantial TAM, estimating 670,000 to 1.34 million potential U.S. heart failure patients for ReadyFlow, with significant revenue implications.
MannKind Corporation (MNKD) Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease Transcript
MannKind Corporation ( MNKD ) Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease November 10, 2025 9:00 AM EST Company Participants Michael Castagna - CEO & Director Conference Call Participants Olivia Brayer - Cantor Fitzgerald & Co., Research Division Benjamin Burnett - Wells Fargo Securities, LLC, Research Division Faisal Khurshid - Leerink Partners LLC, Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good morning, and welcome to MannKind Corporation's investor call to discuss a clinical trial update.
MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
MannKind (MNKD) Tops Q3 Earnings and Revenue Estimates
MannKind (MNKD) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.04 per share a year ago.
MannKind: Durable Cash Engine, Optional Catalysts Pending
MannKind remains a Buy, driven by Tyvaso DPI's strong market position and Technosphere platform optionality. Tyvaso DPI continues robust growth despite Yutrepia's entry, with MNKD's Q2 share at $31 million and overall franchise strength. Recent developments include the acquisition of scPharmaceuticals, pipeline progress, and Afrezza's pediatric sBLA acceptance, supporting modest growth.
MannKind Corporation (MNKD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
MannKind Corporation (NASDAQ:MNKD ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 2:35 PM EDT Company Participants Michael Castagna - CEO & Director Conference Call Participants Ross Cohen - Morgan Stanley Presentation Ross Cohen Great. Thank you all for joining us today, and welcome to the Morgan Stanley Healthcare Conference.
MannKind Corporation (MNKD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
MannKind Corporation (NASDAQ:MNKD ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 4:30 PM EDT Company Participants Michael Castagna - CEO & Director Conference Call Participants Tiago Fauth - Wells Fargo Securities, LLC, Research Division Thomas Smith - Leerink Partners LLC, Research Division Presentation Tiago Fauth Equity Analyst All right. Perfect. Thanks, everyone, for joining us.
MannKind Corporation (MNKD) Presents At Cantor Global Healthcare Conference 2025 Transcript
MannKind Corporation (NASDAQ:MNKD ) Cantor Global Healthcare Conference 2025 September 4, 2025 9:45 AM EDT Company Participants Michael Castagna - CEO & Director Conference Call Participants Olivia Brayer - Cantor Fitzgerald & Co., Research Division Presentation Olivia Brayer Research Analyst All right. Good morning, everyone.
MannKind Corporation (MNKD) Mergers and Acquisition Call Transcript
MannKind Corporation (NASDAQ:MNKD ) Mergers and Acquisition Conference Call August 25, 2025 8:30 AM ET Company Participants Christopher B. Prentiss - Chief Financial Officer Michael E.
MannKind Corporation (MNKD) Q2 2025 Earnings Conference Call Transcript
MannKind Corporation (NASDAQ:MNKD ) Q2 2025 Earnings Call August 6, 2025 9:00 AM ET Company Participants Christopher B. Prentiss - Chief Financial Officer Michael E.
MannKind (MNKD) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
MannKind (MNKD) Reports Break-Even Earnings for Q2
MannKind (MNKD) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.04. This compares to earnings of $0.05 per share a year ago.
